Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Free Report) had its price target boosted by UBS Group from $21.00 to $22.00 in a report published on Monday,Benzinga reports. They currently have a buy rating on the stock.
Separately, William Blair upgraded Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a research report on Tuesday, November 19th.
View Our Latest Research Report on Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited American Depositary Shares Stock Down 1.8 %
Telix Pharmaceuticals Limited American Depositary Shares Company Profile
Telix Pharmaceuticals Limited is a biopharmaceutical company which focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It involved in developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.
Read More
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Sizing Up a New Opportunity for NVIDIA Investors
- The Basics of Support and Resistance
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- How to Read Stock Charts for Beginners
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
